Mood and the menopause

Mental illness is prevalent in all age groups and for women this manifests as affective and anxiety orders. The menopausal transition is a time of increased risk.

The presentation of mood disturbance in the menopause transition appears unique with less depressive symptoms, increased anger, irritability and fluctuation in severity of symptoms. Assessment of psychosocial stressors, menopausal symptoms and mood is necessary.

Most women will benefit from education about the menopause transition and are likely to respond to treatment, if needed.

In the 2007 National Survey of Mental Health and Wellbeing almost half of all respondents aged 18-65 had a mental health problem at some time in their lives. One in five Australians experience a mental illness in any year. The most common illnesses are related to anxiety, then affective and substance use disorders. Women have a higher prevalence of anxiety and depressive disorders (1).

The menopausal transition is a time of increased risk of mood disturbance. Even women with no previous history of depression, particularly those with history of vasomotor symptoms (VMS) or adverse life events are at increased risk of depressive symptoms compared to premenopausal women (2). The risk of a major depressive episode (MDE) is also higher in the peri-menopause compared to the pre-menopause in women with a history of Major Depressive Disorder (MDD) (2).

Women with hysterectomy and ovarian preservation have a 20% higher risk and women with hysterectomy without ovarian conservation have a 44% higher risk of depression (3). Premature ovarian insufficiency is associated with a 20% higher prevalence of depression than the general population (4).

Risk factors for depressive symptoms/disorders are multiple and include VMS, previous mood disorders including prior MDD, reproductive related mood disturbance (severe premenstrual syndrome (PMS) or postpartum depression), other health factors, psychological and socioeconomic factors, and hormonal changes such as variability in FSH and oestradiol.

The clinical presentation of depression/mood disturbance at the menopause transition may be unique, with less sadness, increased anger, irritability and paranoia which can fluctuate in severity compared to younger women. Many symptoms overlap; difficulties with sleep, concentration, energy and libido could be attributed to classic depressive symptoms or, equally, to mood disturbance related to the menopausal transition. Furthermore, it has been reported that women describe an

www.menopause.org.au

Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person’s circumstances and should always be discussed with that person’s own healthcare provider. This Information Sheet contains copyright or otherwise protected material. Reproduction of this Information Sheet by Australasian Menopause Society Members and other health professionals for clinical practice is permissible. No other reproduction or transmission is permitted in any form or by any information storage and retrieval systems except as permitted under the Copyright Act 1968 or with prior written permission from the copyright owner. ID:2021-07-26
“on-off” phenomenon with sadness or irritability which may last for minutes to hours and spontaneously resolve, similar to what can be seen with PMS (5), making it harder to establish a temporal association between the psychological and physical symptoms. However, a unique presentation at the menopause has not been shown in research, which is likely contributed to by a lack of menopause-specific screening tools to assess mood disturbance. Validated tools exist to assess the severity of depressive symptoms (eg Patient Health Questionnaire-9) and menopause related quality of life questionnaires (eg Greene Climacteric Scale). Additionally, although anxiety disorders are the most common mental health disorders (2) and anxiety and affective disorders have a separate DSMIV/ICD10 criteria, these are not assessed separately, nor consistently, in studies looking at either depression or anxiety (6) in the menopause making menopausal depression an umbrella term. More recently, a questionnaire, Meno-D, developed by Kulkani et al. (7) has been validated as a screening questionnaire to rate the severity of symptoms related to depression in the perimenopause to be used by clinicians, in research and as a self-assessment tool. Using 12 items, graded from 0-4, it identifies five subcategories: somatic, cognitive, self, sleep and sexual function.


Management

Lifestyle changes which may modify mood should be implemented as part of a holistic model of care. A meta-analysis found that low- moderate intensity exercise reduces depressive symptoms in midlife and older women (8). Clinical trials have demonstrated the benefit of cognitive behavioural therapy (9).

Antidepressants may be indicated for perimenopausal depression. Selective serotonin reuptake inhibitors and serotonin noradrenaline reuptake inhibitors have also been shown to improve VMS. It should be noted that some SSRI/SNRIs can cause sweating. While SSRIs are generally considered first line, desvenlafaxine has been shown to be efficacious in two randomised, double blind placebo-controlled trials in peri- and post-menopausal women (2). Of note, the SSRIs and SNRIs have side effects that may result in sexual dysfunction.

Use of SSRIs in women with breast cancer using tamoxifen. There have been concerns that certain SSRIs (paroxetine and fluoxetine) may reduce the active metabolite of tamoxifen.

Menopausal hormone therapy (MHT) is not a first line treatment for depressive disorders. MHT may be of particular benefit for mood and sleep quality in women experiencing VMS and can be considered in combination with antidepressants. Evidence from RCTs suggests MHT is as effective as other antidepressants in perimenopausal women but is ineffective in post-menopausal women (2) suggesting a window of opportunity for its use in the perimenopause. Some evidence exists for the efficacy of MHT in the prevention of the onset of depression in euthymic women; at present there is insufficient evidence to recommend prescribing MHT for prevention of depression.

www.menopause.org.au

Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person’s circumstances and should always be discussed with that person’s own healthcare provider. This Information Sheet contains copyright or otherwise protected material. Reproduction of this Information Sheet by Australasian Menopause Society Members and other health professionals for clinical practice is permissible. No other reproduction or transmission is permitted in any form or by any information storage and retrieval systems except as permitted under the Copyright Act 1968 or with prior written permission from the copyright owner. ID:2021-07-26
References:
5. Worsley, R et al. The association between vasomotor symptoms and depression during the perimenopause: a systematic review. Maturitas 2012;77:111-117